Deutsche Bank Aktiengesellschaft Reiterates Hold Rating for Smith & Nephew (LON:SN)

Smith & Nephew (LON:SN)‘s stock had its “hold” rating reiterated by research analysts at Deutsche Bank Aktiengesellschaft in a research note issued on Tuesday, Digital Look reports. They presently have a GBX 1,250 target price on the stock. Deutsche Bank Aktiengesellschaft’s target price would suggest a potential upside of 19.22% from the stock’s current price.

A number of other analysts also recently weighed in on SN. Citigroup downgraded shares of Smith & Nephew to a “buy” rating in a research report on Friday, July 10th. JPMorgan Chase & Co. lowered their target price on shares of Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating for the company in a research note on Thursday, August 6th. Royal Bank Of Canada cut their target price on shares of Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating on the stock in a report on Thursday, August 6th. Jefferies Financial Group reissued a “buy” rating and set a GBX 1,500 price target on shares of Smith & Nephew in a research report on Friday, September 4th. Finally, Shore Capital Group reissued a “buy” rating and issued a GBX 1,000 price target on shares of Smith & Nephew in a report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of GBX 1,293.33.

Smith & Nephew Trading Up 4.0%

Shares of LON SN opened at GBX 1,048.50 on Tuesday. The company has a quick ratio of 0.84, a current ratio of 2.14 and a debt-to-equity ratio of 73.07. The company has a market cap of £11.49 billion, a price-to-earnings ratio of 37.75, a PEG ratio of 0.46 and a beta of 0.69. The company has a 50-day simple moving average of GBX 1,106.12 and a 200-day simple moving average of GBX 1,155.57.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.